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Abstract: c-Met, a member of the receptor tyrosine kinase family, is involved in a wide 
range of cellular processes, including tumor survival, cell growth, angiogenesis and metastasis, 
and resulting in overexpression in many human cancers, leading to a constitutive activation 
of the downstream pathways. Recently identified MicroRNAs are a family of small noncoding 
RNA molecules, extensively studied in cancer, that exert their action by inhibiting gene 
expression at the posttranscriptional level in several biological processes. Aberrant regulation 
of microRNAs expression has been implicated in the pathogenesis of different human 
neoplasia. Several publications point out the connections between c-Met and its ligand 
hepatocyte growth factor (HGF) and microRNAs. This review summarizes the current 
knowledge about the interplay between c-Met/HGF and microRNAs and provides evidence that 
microRNAs are a novel and additional system to regulate c-Met expression in tumors. In the 
future, microRNAs connected to c-Met may provide an additional option to inhibiting this 
oncogene from orchestrating an invasive growth program. 
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1. The HGF/c-Met Pathway 
The c-Met proto-oncogene was originally identified as a fusion gene (tpr-c-Met) in a chemically 
transformed human osteosarcoma cell line [1]. The gene for c-Met is located on chromosome 7q21–q31 
and encodes for a single precursor that is posttranscriptionally processed, giving rise to a 50 kDa 
extracellular α-chain and a transmembrane 140 kDa β-chain, which are linked by disulfide bonds [2].  
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c-Met’s ligand has been identified as the hepatocyte growth factor (HGF) which is secreted by fibroblasts 
and smooth muscle cells [3,4]. Ligand-induced c-Met dimerization leads to phosphorylation of specific 
tyrosine residues (Tyr1230, Tyr1234 and Tyr1235) in the kinase domain, which, in turn, induces 
autophosphorylation of the carboxy-terminal bidentate substrate-binding site (Tyr1349 and Tyr1356) of 
c-Met [5]. 
Cytoplasmic signaling cascades, mainly mediated by PI3K–AKT and the ERK pathways, modulate 
cell survival and trigger changes to the plasma membrane, control cell migration and cell adhesion 
through downstream molecules that include cadherins, integrins, focal adhesion kinase and paxillin 
pathways [5,6]. 
Thus, the HGF/c-Met activated signaling promotes a complex biological program named  
“invasive growth” that results in stimulation of cell motility, invasion, and protection from apoptosis. 
The c-Met oncogene is deregulated in different human tumors at multiple levels, mainly through 
transcriptional deregulation, gene amplification, inadequate degradation, receptor crosstalk or synergies in 
the downstream signaling. 
Recently identified microRNA (miRs) are noncoding small RNA (20–22 nucleotides) that have the 
potential to regulate at least 20%–30% of all human transcripts and are therefore involved in almost all 
basic signaling pathways. The regulation of miRNAs biogenesis and function has been extensively 
reviewed elsewhere [7,8]. Dysregulated miRs contribute to a variety of pathological events, including 
cancer. Thus, miRs are able to inhibit the expression of major tumor-related genes in carcinogenesis, 
acting themselves as oncogenes or oncosuppressors [9,10]. 
Recent evidences show that alteration of miR expression was observed in different human tumor 
types, and their key role in cancer pathogenesis and response to therapy has been proven [11,12]. 
In recent years, a rapidly growing number of subsequent papers refined the knowledge about the 
interplay between c-Met/HGF and miRNAs. In this review, functional studies on regulation of c-Met 
and miRNAs will be summarized in detail. 
2. MicroRNAs Regulating c-Met 
2.1. miR-34 Family Members 
The miR-34 family, consist of miR-34a, miR-34b and miR-34c that are frequently silenced in a 
variety of tumors, indicating their role in tumorigenesis. These three miR-34s are produced from  
two transcriptional units. MiR-34a is transcribed from chromosome 1, a locus deleted in neuroblastoma, 
breast, thyroid, and cervical cancer [13–16], while miR-34b and miR-34c are co-transcribed from a region 
on chromosome 11. 
Several studies pointed out miR-34 as one of the main miR-regulating c-Met. 
Indeed He and colleagues demonstrated for the first time the direct interaction between miR-34 and 
c-Met in mouse embryonic fibroblasts (MEF) cells [17]. Hereafter, c-Met was established as a bona fide 
miR-34 target in different tumors such as melanoma, lung, colon, breast and gastric cancer cells [18]. 
Particularly in glioblastoma and ovarian cancer, miR-34 family members’ a–b–c expression was 
inversely correlated with c-Met expression [19–21].  
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Moreover, it was reported by the same authors that miR-34 inhibits cell invasion, proliferation  
and tumorigenesis, whereas c-Met over-expression partially reversed the cell death and cell cycle  
arrest induced by miR-34 in brain tumors and glioma [20,21]. Importantly, miR-34 blocked the 
phosphorylation signal cascade of c-Met, Akt, ERK and compromised c-Met-driven invasion [18]. 
In a study conducted by Dang et al., it has been demonstrated that the enforced expression of  
miR-34a mimic enhanced the effect of cell proliferation inhibition and caspase activity induction of 
agents targeting c-Met in hepatocellular carcinoma [22]. 
Cai and colleagues identified an inverse relationship between the expression of miR-34c and c-Met, 
in 10-paired fresh samples from tumor tissues and adjacent normal tissues of laryngeal carcinoma, 
showing that down-regulated miR-34c is a critical factor that contributes to malignancy in human 
laryngeal carcinoma by targeting of c-Met [23]. 
Zhou and collegues demonstrated additional evidence of the pivotal role played by miR-34a in 
HGF/MET signaling. They found that miR-34 was able to overcome HGF-induced gefitinib resistance 
in HCC827 and PC-9 cells by modulating c-Met and downstream pathway molecules, suggesting  
a new strategy for reversing HGF-induced resistance to gefitinib in lung cancers [24]. 
2.2. miR-199a-3p 
The miR-199–miR-214 cluster is of particular interest because it is downregulated in the majority  
of hepatocellular carcinomas (HCCs) [25,26], bladder [27], ovarian [28], and renal carcinomas [29]  
and in cancer-derived cell lines in experimental neoplastic and preneoplastic conditions [30]. 
Both Kim and Migliore identified the c-Met proto-oncogene as a target of the miR-199a-3p [18,31]. 
Particularly, they demonstrated that miR-199a-3p inhibits not only proliferation, but also motility and 
invasive capabilities of tumor cells by downregulating both c-Met and its downstream effector  
ERK2 [31]. 
It was recently reported that serum concentration of HGF, the c-Met receptor ligand, was significantly 
elevated in renal cell carcinoma (RCC) patients compared to healthy individuals, thereby suggesting that 
miR-199a-3p impairs HGF/c-Met signaling pathway, including STAT3, mTOR and ERK1/2, which is 
crucial for RCC development, thus also suggesting that this miR may serve as a potential target for  
RCC therapy [29]. 
Minna and colleagues reported downregulation of miR-199a-3p in papillary thyroid cancer  
(PTC) specimens and cell lines, and demonstrated that its restoration in PTC cells reduces c-Met and 
mTOR protein levels, impairing migration and proliferation and, more interestingly, inducing lethality  
through an unusual form of cell death similar to methuosis, caused by macropinocytosis dysregulation, 
unveiling interesting networks including HGF and macropinocytosis pathways [32]. 
2.3. miR-340 
miR-340 is downregulated in aggressive breast cancer cell lines and breast cancer tissue specimens, 
indicating its tumor suppression role. Wu and colleagues demonstrated that miR-340 inhibits c-Met and 
consequently MMP-2 and MMP-9 expressions by direct targeting of the c-Met gene [33]. 
Another research group reported that low expression of miR-340 is associated with poor prognosis in 
colorectal cancer and demonstrated that pre-miR-340 administration inhibited growth of colon cancer 
Biomedicines 2015, 3 35 
 
 
cells and suppressed c-Met expression in vitro. Interestingly, they observed that the colorectal cancer 
patients with low miR-340 and high c-Met expression had the worst prognosis [34,35]. 
2.4. miR-148a 
MiR-148a downregulation is reported in multiple malignancies by different authors, and,  
its over-expression inhibits growth of pancreatic and prostate cancer cells, promotes apoptosis  
of colorectal cancer, suppresses angiogenesis of breast cancer and represses metastatic potential of 
gastric cancer-derived cell lines [36–40]. 
Zhang and colleagues proved that miR-148a directly target c-Met and abrogate c-Met/Snail signaling 
in hepatoma cells, providing novel mechanistic insights into the role of miR-148a in ephitelial 
mesenchymal transition (EMT) and metastasis [41]. 
Another study confirmed a significant down-regulation of miR-148a in HCC, indicating that this miR 
exerted its tumor-suppressive effect by regulating the c-Met oncogene, regardless of the DNMT1,  
the DNA methyltransferase 1, expression level [42,43]. 
2.5. miR-1 
Several papers showed the direct interaction between miR-1 and c-Met. 
Nasser and colleagues have published the first evidence of the direct binding between miR-1 and the 
3' UTR of c-Met, reporting that exogenous miR-1 significantly reduced its expression, thereby reducing 
cell migration and motility of A549 cells in a c-Met-mediated manner [44]. A significantly lower level of 
miR-1 compared to the higher level of c-Met expression was observed in aggressive PTC, in chordoma 
tissues and human primary lung cancer tissues and cell lines [44–46]. 
Recently, Duan and colleagues showed that miR-1 was downregulated in 93.7% of chordoma tissues 
and its expression was inversely correlated with c-Met expression, indicating that suppressed miR-1 
expression in chordoma may in part be a driver for tumor growth, and that miR-1 has the potential to 
serve as a prognostic biomarker and therapeutic target for chordoma patients [46]. 
Novello and colleagues demonstrated that the ectopic expression of miR-1 in the U2-OS osteosarcoma 
cell lines, significantly reduced cell proliferation and cell invasiveness correlated with c-Met  
down-regulation. They performed a miR profiling in osteosarcoma clinical samples and showed that the 
expression of miR-1 together with miR-133b may control cell proliferation and cell cycle through c-Met 
protein expression modulation [47]. 
Another study conducted by Reid et al. showed that miR-1 can have a tumor-suppressor function in 
colorectal cancer by directly downregulating c-Met oncogene both at the RNA and protein levels and 
that reexpression of miR-1 leads to c-Met-driven reduction of cell proliferation and motility, identifying 
miR-1 downmodulation as one of the events that could enhance colorectal cancer progression [48]. 
Migliore’s group observed that miR-1 and miR-206 are highly expressed in skeletal muscle and 
investigated their role in the development of rhabdomyosarcoma. Interestingly, miR-1/206 expression 
levels were inversely correlated with c-Met, demonstrating that miR-1/206 suppressed c-Met expression 
in rhabdomyosarcoma and could function as a potent tumor suppressor in c-Met-over-expressing  
tumors [49]. 
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2.6. Other miRNAs Regulating c-Met/HGF 
Mariani and colleagues showed that miR-193a-5p was significantly over-expressed in patients 
undergoing neo-adjuvant chemotherapy (NACT) for ovarian cancer. They proved that patients who 
relapsed shortly after NACT exhibited the highest relative basal expression of both HGF and c-Met, 
indicating that mir-193a-5p, HGF and c-Met expression may help select patients that would benefit from 
these therapeutic regimens [50]. 
Another study conducted in HCC established that miR-26a exerted its antiangiogenesis function,  
at least in part, by inhibiting directly HGF and its downstream signaling pathway, in turn suppressing 
VEGFA production in HCC cells and impairing VEGFR2-signaling in endothelial cells [51]. 
The expression of miR-410 was inversely associated with c-Met in human glioma tissues. Thus,  
Chen demonstrated that miR-410 directly targeted c-Met in glioma cells and suggested they may 
function as a tumor suppressor in human gliomas [52]. 
In HCC cells, Buurman reported that miR-449 directly targets c-Met, leading to an increase of 
apoptosis and growth arrest of liver cancer cell lines. Expression of miR-449 slows growth of HCC 
xenograft tumors in mice, suggesting that this miR might function as a tumor suppressor [53]. 
MiR-198 directly targets c-Met via its 3' UTR and consequently its overexpression diminished  
HGF-induced phosphorylation of p44/42 MAPK in HCC cells, leading to an inhibition of cell migration 
and invasion in a c-Met-dependent manner [54]. 
A study conducted by Lee illustrated that miR-7515 plays an important role in the proliferation and 
migration of lung cancer cells through c-Met regulation. Indeed, miR-7515 downregulate in lung cancer 
compared with normal human lung cells and tissues and directly suppress c-Met, subsequently leading 
to decreased cell proliferation, migration and invasion in a lung cancer cell line [55]. 
Guo and colleagues showed that miR-101 over-expression decreased c-Met expression at both mRNA 
and protein levels inhibiting T24 cell lines migration and invasion [56,57]. 
Korhan and colleagues found an inverse correlation between miR-181a-5p and c-Met expression in 
normal, cirrhotic and HCC liver tissues, and demostrated that miR-181a-5p is a direct target of c-Met. 
Furthemore, they showed that the knockdown of this miR leads to the activation of c-Met-mediated 
oncogenic signaling in hepatocarcinogenesis, thereby indicating that the reintroduction of tis miR may 
be a strategy to reduce c-Met activity [58] (Figure 1). Table 1 summarizes miRs regulating c-Met and 
other targets, the methods and the conditions by which the regulation was characterized. 
3. Regulatory Circuits Controlled by c-Met and miRs 
Important studies have pointed out that by regulating the expression of specific miRs, c-Met orchestrates 
the convergence of several EMT-associated pathways, including Dicer, SRC, PKC-ε and AKT, suggesting 
the possibility that c-Met targeting could be a strategy to control EMT and cancer progression. 
  




Figure 1. Schematic representation of organ-specific miR involved in HGF/c-MET regulation. 
Particularly, different studies conducted by Croce’s lab showed that c-Met is a direct regulator of  
miR expression. 
In 2009, Garofalo et al., showed that c-Met upregulates miR-221 and 222 expression through  
Jun transcriptional activation, which, in turn, confers resistance to TRAIL-induced cell death and 
increases tumorigenicity of lung and liver cancer cells by targeting PTEN and TIMP3 [59]. 
Previous studies reported that c-Met induces gefitinib resistance through persistent PI3K-AKT and 
ERK signaling activation [60]. 
In another paper, Garofalo et al. reported that c-Met expression downregulates miR-103 and miR-203, 
inducing gefitinib resistance, and epithelial−mesenchymal transition in non-small cells lung cancer 
(NSCLCs). They also showed that c-Met and EGF receptors induced the down-regulation of miR-30b 
and miR-30c expression [61]. 
The relationship between c-Met and miR-221/222 was confirmed by Acunzo et al., which found that 
miR-130a overexpression reduced miR-221/222 levels in a c-Met-dependent manner. This finding 
highlighted how miR-130a, by targeting c-Met, was able to reduce miR-221/222 expression and, 
accordingly, TRAIL resistance in NSCLC cells. Thus, targeting c-Met and modulating miR-221/222 
could be used not only to sensitize NSCLC to TRAIL-inducing apoptosis, but also in the prevention and 
inhibition of lung cancer [62]. 
The same group in 2013 demostrated that c-Met induces miR-23a-27a-24-2 expression. Furthermore, 
a member of this cluster, miR-27a, is able to downregulate c-Met and EGFR by either targeting directly 
their 3' UTRs or indirectly, by targeting Sprouty2. In summary, Acunzo et al. demonstrated a mechanism 
for c-Met regulation of EGFR expression in NSCLC that may give rise to further strategies for lung 
cancer treatment in the future [63]. 
Additionally, Migliore and colleagues identified a feedback loop between miR-1 and c-Met, resulting 
in their mutual regulation. They showed that concomitant downregulation of miR-1 and up-regulation 
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of MACC1 leads to a c-Met induction and promotes cancer metastatis in colon cancer cells [49]  
(Figure 2). 




Validation Methods Disease or Conditions References
miR-34 
MET 
Reporter assay,  
qRT-PCR, WB 








Reporter assay,  
qRT-PCR, WB Other 
HEK293 [64] 
miR-340-5p MET 
IHC, Reporter assay, 
qRT-PCR, WB, Other 
primary breast cancer [33] 
miR-199a-3p 
MET MAPK1 
Reporter assay,  
WB, microarray 
A549 cells [31] 
MET 




Reporter assay  
and WB 
Hepatoma cells [38] 
miR-1 MET 




MET MicroArray Ovarian cancer [50] 
TP73 
Reporter assay,  
qRT-PCR, WB 
JHU-029, A549 [65] 
miR-26a 
HGF Reporter assay HCC [51] 
PTEN 
Reporter assay  
and WB 
Thyroid cancer [66] 
miR-410 
MET 
Reporter assay  
and WB 
Glioma cell lines [52] 
MET Reporter assay HCC cell lines [53] 
CDC25A 
Reporter assay,  
qRT-PCR, WB, other 





qRTPCR, WB, other 
prostate carcinoma cell lines [68] 
miR-198 MET Reporter assay HCC cell lines [54] 
miR-7515 MET Reporter assay Lung cancer cells and tissues [55] 
miR-101 
MET qRT-PCR and WB Bladder cancer [57] 
MYCN 




Reporter assay,  
qRT-PCR and WB 
HCC [58] 
The abbreviations used are: miR, microRNA; qRT-PCR, quantitative real-time-PCR; WB, Western blot; 
Immunohistochemistry, IHC; HCC, Human hepatocellular carcinoma. 




Figure 2. Schematic representation of regulatory circuits controlled by c-Met and miRNAs. 
Blue arrows indicate an induction of downstream signal trasduction, wherease blue shapes 
indicate a block of downstream signal trasduction. Light gray arrow indicates a reduction of 
miRs, the dark gray arrow indicates an increase of miRs. 
4. Conclusions and Outlook 
Over-expression of c-Met contributes to the development a wide variety of human tumors. 
Counteracting the tumor-promoting activity of c-Met is therefore an attractive anticancer strategy  
that is currently being explored. Among different approaches targeting different levels of the c-Met 
expression, the characterization of the interplay between c-Met and miRs give another layer of targeting 
opportunities. Thus the rapidly growing understanding of the biology of miRs in cancer as well as the 
development in RNA-mediated therapeutic approaches in recent years, promises new and exciting modes 
of specific targeting in cancer. 
In conclusion, further understanding of the effect of miRs on the c-Met expression will help to 
understand the pathogenesis of several types of cancer and provides a basis for novel targeted therapies 
for cancer treatment. 
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